Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Elixio is a marine collagen-based nutraceutical supplement developed and marketed by Bioquest Pharmaceuticals. It is formulated as a liquid oral "shot" containing hydrolyzed marine collagen, hyaluronic acid, astaxanthin, and a comprehensive blend of vitamins and minerals, including Vitamin C, Vitamin D, Biotin, Zinc, and Selenium. The product is designed to support the health of skin, hair, and nails by promoting protein synthesis, maintaining skin elasticity, and providing antioxidant protection. Although Bioquest Pharmaceuticals is primarily an ophthalmic company and Elixio is sometimes categorized under eye care nutraceuticals due to its hyaluronic acid content, it is a systemic oral supplement intended for overall wellness rather than a topical ophthalmic medication for specific ocular diseases.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Elixio.